Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

AGM Statement

8 Sep 2011 07:00

RNS Number : 8405N
Immunodiagnostic Systems Hldgs PLC
08 September 2011
 



 

 

Immunodiagnostic Systems Holdings plc

("IDS" or "the Company")

 

AGM Statement

 

Immunodiagnostic Systems Holdings plc (AIM: IDH), a leading producer of specialist diagnostic testing kits for the clinical and research markets, will hold its Annual General Meeting today at 3.00pm at the offices of Brewin Dolphin Limited at 12 Smithfield Street, London EC1A 9BD.

 

At the meeting Chairman, David Evans, will make the following statement to shareholders:

 

"Revenues to 31 August are £22.6m compared with £18.4m for the comparative period in 2010. We have seen continued growth in our IDS-iSYS revenues which have grown £4.4m over the comparative period. As of 31 August 299 instruments have been sold or placed an increase of 58 systems since the year end and we anticipate a further 15 instruments being placed or sold in September. Average revenue per instrument is £88k compared to £72k in August 2010.

 

Our revenues are traditionally weighted to the second-half of the year and we believe this year that the trend ratio will be higher this financial year reflecting both a seasonally quieter July and August and also higher anticipated reagent / instrument sales pull-through and the anticipated continued resilience of manual product sales in the second-half.

 

The process of transition in terms of the Board has continued since the year end. We have added Roland Sackers, the CFO of QIAGEN N.V. and at the end of this meeting Anthony Martin, who has a long-established track record in the diagnostics and life sciences space, will succeed me as Chairman.

We remain active in examining the potential for licensing-out our automated IDS-iSYS platform into other disease areas not served by the Company and which can help drive value. We have ongoing discussions in autoimmune disease and in coagulation testing outside of Europe and we will keep you updated as discussions progress.

 

Finally we continue to seek acquisitions where we believe we can either add value to our existing franchise in bone and mineral disease or where we can validly exploit the IDS-iSYS asset base.

 

A more detailed trading update will be given week commencing 3rd October."

 

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel: 0191 519 0660

Ian Cookson, Chief Executive Officer

Paul Hailes, Finance Director

 

 

 

Brewin Dolphin

Tel: 0845 213 4930

Matt Davis

Sean Wyndham-Quin

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

paul.mcmanus@walbrookpr.com

Fiona Henson

fiona.henson@walbrookpr.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMSSAFWWFFSEFU
Date   Source Headline
27th Oct 20174:23 pmRNSTransaction in Own Shares
23rd Oct 20175:38 pmRNSTransaction in Own Shares
20th Oct 20174:30 pmRNSH1 Trading Update
5th Oct 20179:49 amRNSHolding(s) in Company
5th Oct 20179:42 amRNSHolding(s) in Company
5th Oct 20179:39 amRNSHolding(s) in Company
2nd Oct 20176:08 pmRNSHolding(s) in Company
22nd Sep 20177:25 amRNSTransaction in Own Shares
20th Sep 20176:09 pmRNSTransaction in Own Shares
18th Sep 20173:23 pmRNSTransaction in Own Shares
10th Aug 20172:00 pmRNSLaunch of IDS-iSYS
10th Aug 20178:37 amRNSTransaction in Own Shares
9th Aug 20177:00 amRNSTransaction in Own Shares
2nd Aug 20179:30 amRNSDirector/PDMR Shareholding
2nd Aug 20178:33 amRNSHolding(s) in Company
2nd Aug 20178:30 amRNSHolding(s) in Company
27th Jul 20173:45 pmRNSResult of AGM
27th Jul 20178:00 amRNSTransaction in Own Shares
27th Jul 20177:00 amRNSAGM Statement
24th Jul 20177:00 amRNSTransaction in Own Shares
3rd Jul 20174:12 pmRNSDirector/PDMR Shareholding
28th Jun 20178:28 amRNSDirector/PDMR Shareholding
22nd Jun 20175:33 pmRNSDirector/PDMR Shareholding
21st Jun 20177:30 amRNSPublication of Annual Report and Accounts
21st Jun 20177:01 amRNSShare Buyback Programme
21st Jun 20177:00 amRNSFinal Results
21st Apr 20177:00 amRNSTrading Update
23rd Mar 20179:14 amRNSDirector/PDMR Shareholding
13th Mar 20178:31 amRNSDirectorate Change
1st Mar 201710:01 amRNSLaunch of IDS-iSYS InaKtif MGP assay
24th Feb 20173:31 pmRNSUpdate on CEO Appointment
7th Feb 20172:46 pmRNSHolding(s) in Company
2nd Feb 20173:14 pmRNSLaunch of IDS-iSYS ACTH assay
26th Jan 20173:05 pmRNSHolding(s) in Company
20th Jan 20174:24 pmRNSDirector Dealing
20th Jan 201710:30 amRNSHolding(s) in Company
19th Jan 20171:12 pmRNSDirectorate Change
18th Jan 201712:26 pmRNSHolding(s) in Company
11th Jan 20173:14 pmRNSDirector/PDMR Shareholding
5th Jan 20175:35 pmRNSHolding(s) in Company
5th Jan 20174:38 pmRNSHolding(s) in Company
25th Nov 20168:00 amRNSHalf-year Report
21st Oct 20167:00 amRNSH1 Trading Update
19th Oct 20167:00 amRNSLaunch of IDS-iSYS Total Testosterone assay
28th Jul 20163:18 pmRNSResult of AGM
28th Jul 20167:00 amRNSAGM Statement
11th Jul 201611:46 amRNSDirector/PDMR Shareholding
5th Jul 201610:07 amRNSDirector/PDMR Shareholding
30th Jun 20166:15 pmRNSDirector/PDMR Shareholding
28th Jun 20166:13 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.